The Growth Hormone Secretagogue Receptor Type 1 pipeline drugs market research report outlays comprehensive information on the Growth Hormone Secretagogue Receptor Type 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Growth Hormone Secretagogue Receptor Type 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Oncology, Central Nervous System, Metabolic Disorders, and Gastrointestinal which include the indications Cancer Anorexia-Cachexia Syndrome, Alzheimer’s Disease, Traumatic Brain Injury, Obesity, Constipation, and Functional (Non Ulcer) Dyspepsia. It also reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 targeted therapeutics development with respective active and dormant or discontinued products.

The Growth Hormone Secretagogue Receptor Type 1 pipeline targets constitutes close to 20 molecules. Out of which, approximately 18 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 4, 1, 10, and 2 respectively. Similarly, the universities portfolio in Phase II, and Discovery comprises 1, and 1 molecule.

Growth Hormone Secretagogue Receptor Type 1 overview

Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin. Ghrelin is an appetite-regulating factor secreted from peripheral organs via binding to the receptor resulting in the secretion of growth hormone by the pituitary gland. The pathway activated by binding of ghrelin to the growth hormone secretagogue receptor, GHSR1a, regulates the activation of the downstream mitogen-activated protein kinase, Akt, nitric oxide synthase, and AMPK cascades in different cellular systems. Inverse agonists for the ghrelin receptor could be particularly interesting for the treatment of obesity.

For a complete picture of Growth Hormone Secretagogue Receptor Type 1’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.